Höck A, Spohr G, Schmitz M, Notohamiprodjo G, Porschen R, Vyska K, Freundlieb C, Shreeve W W, Feinendegen L E
J Nucl Med. 1986 Oct;27(10):1533-9.
(17-123I)-Iodoheptadecanoic acid ([123I]HA) was used for dynamic planar scintigraphy of the liver in normal individuals (control I), in patients without liver disease but with elevated serum cholesterol and/or triglycerides (control II), and in patient groups with alcohol-induced fatty liver (PG I), fatty liver not due to alcohol (PG II), alcohol-induced liver cirrhosis (PG III), or liver cirrhosis of the posthepatitic type (PG IV). Tracer uptake and elimination time were assayed in different liver regions; mean elimination time was expressed for total liver. In control I, tracer uptake was homogeneous, and mean elimination time was 20.7 +/- 5.3 min without significant local variations. In control II, tracer uptake was reduced but homogeneous and mean elimination time was 59.4 +/- 35.8 min with some local variations. In PG I, uptake was reduced and inhomogeneous and elimination time was the same as in control I, irrespective of cholesterol and triglyceride values. In PG II, uptake was the same as in PG I but mean elimination time was 48 +/- 8.1 min with some local variations. In PG III, uptake was extremely reduced and spotty and elimination time correlated with the severity of disease from 19 to 881 min in different liver regions.
(17-¹²³I)-碘十七烷酸([¹²³I]HA)用于正常个体(对照组I)、无肝病但血清胆固醇和/或甘油三酯升高的患者(对照组II)以及酒精性脂肪肝患者组(PG I)、非酒精性脂肪肝患者组(PG II)、酒精性肝硬化患者组(PG III)或肝炎后型肝硬化患者组(PG IV)的肝脏动态平面闪烁显像。测定不同肝区的示踪剂摄取和消除时间;以全肝表示平均消除时间。在对照组I中,示踪剂摄取均匀,平均消除时间为20.7±5.3分钟,无明显局部差异。在对照组II中,示踪剂摄取减少但均匀,平均消除时间为59.4±35.8分钟,有一些局部差异。在PG I中,摄取减少且不均匀,消除时间与对照组I相同,与胆固醇和甘油三酯值无关。在PG II中,摄取与PG I相同,但平均消除时间为48±8.1分钟,有一些局部差异。在PG III中,摄取极度减少且呈斑点状,不同肝区的消除时间与疾病严重程度相关,为19至881分钟。